company background image
1783

Maxigen Biotech TWSE:1783 Stock Report

Last Price

NT$40.55

Market Cap

NT$3.1b

7D

-7.8%

1Y

-19.1%

Updated

30 Sep, 2022

Data

Company Financials
1783 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends2/6

1783 Stock Overview

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, the United States, Europe, rest of Asia, and internationally.

Maxigen Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Maxigen Biotech
Historical stock prices
Current Share PriceNT$40.55
52 Week HighNT$61.60
52 Week LowNT$34.20
Beta0.73
1 Month Change-17.92%
3 Month Change-6.13%
1 Year Change-19.06%
3 Year Change63.51%
5 Year Change70.74%
Change since IPO-19.38%

Recent News & Updates

Shareholder Returns

1783TW Personal ProductsTW Market
7D-7.8%-5.8%-5.5%
1Y-19.1%-6.2%-19.3%

Return vs Industry: 1783 underperformed the TW Personal Products industry which returned -6.2% over the past year.

Return vs Market: 1783 matched the TW Market which returned -19.3% over the past year.

Price Volatility

Is 1783's price volatile compared to industry and market?
1783 volatility
1783 Average Weekly Movement7.5%
Personal Products Industry Average Movement5.9%
Market Average Movement5.2%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 1783 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1783's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
1998n/aChing-Ting Chenhttps://mbi-bio.com

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, the United States, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; BestAid, a collagen bone graft; FormaSetin, an injectable bone void filler; and MaxiBone, a calcium phosphate ceramic.

Maxigen Biotech Fundamentals Summary

How do Maxigen Biotech's earnings and revenue compare to its market cap?
1783 fundamental statistics
Market CapNT$3.14b
Earnings (TTM)NT$98.69m
Revenue (TTM)NT$557.38m

31.6x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1783 income statement (TTM)
RevenueNT$557.38m
Cost of RevenueNT$263.35m
Gross ProfitNT$294.04m
Other ExpensesNT$195.35m
EarningsNT$98.69m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.28
Gross Margin52.75%
Net Profit Margin17.71%
Debt/Equity Ratio0.0%

How did 1783 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

56%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 1783 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1783?

Other financial metrics that can be useful for relative valuation.

1783 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.5x
Enterprise Value/EBITDA21.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 1783's PE Ratio compare to its peers?

1783 PE Ratio vs Peers
The above table shows the PE ratio for 1783 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average14.7x
1731 Maywufa
15xn/aNT$2.4b
8480 Taisun Int'l (Holding)
17.1xn/aNT$3.3b
6523 Dr. Wu Skincare
12.1x3.7%NT$4.3b
6703 Shiny Brands Group
14.4xn/aNT$2.0b
1783 Maxigen Biotech
31.6xn/aNT$3.1b

Price-To-Earnings vs Peers: 1783 is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the peer average (14.7x).


Price to Earnings Ratio vs Industry

How does 1783's PE Ratio compare vs other companies in the Asian Personal Products Industry?

Price-To-Earnings vs Industry: 1783 is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the Asian Personal Products industry average (25.6x)


Price to Earnings Ratio vs Fair Ratio

What is 1783's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1783 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1783's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 1783 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1783 (NT$40.55) is trading below our estimate of fair value (NT$127.84)

Significantly Below Fair Value: 1783 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Maxigen Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.8%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maxigen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Maxigen Biotech performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


26.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1783 has high quality earnings.

Growing Profit Margin: 1783's current net profit margins (17.7%) are higher than last year (16.1%).


Past Earnings Growth Analysis

Earnings Trend: 1783's earnings have grown significantly by 26.3% per year over the past 5 years.

Accelerating Growth: 1783's earnings growth over the past year (30.5%) exceeds its 5-year average (26.3% per year).

Earnings vs Industry: 1783 earnings growth over the past year (30.5%) exceeded the Personal Products industry -11.6%.


Return on Equity

High ROE: 1783's Return on Equity (8.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Maxigen Biotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1783's short term assets (NT$863.4M) exceed its short term liabilities (NT$113.7M).

Long Term Liabilities: 1783's short term assets (NT$863.4M) exceed its long term liabilities (NT$20.0K).


Debt to Equity History and Analysis

Debt Level: 1783 is debt free.

Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 28.8%.

Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Maxigen Biotech current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.80%

Current Dividend Yield

Dividend Yield vs Market

Maxigen Biotech Dividend Yield vs Market
How does Maxigen Biotech dividend yield compare to the market?
SegmentDividend Yield
Company (Maxigen Biotech)1.8%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.0%
Industry Average (Personal Products)3.8%
Analyst forecast in 3 Years (Maxigen Biotech)n/a

Notable Dividend: 1783's dividend (1.8%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.57%).

High Dividend: 1783's dividend (1.8%) is low compared to the top 25% of dividend payers in the TW market (7.03%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 1783 has been paying a dividend for less than 10 years.

Growing Dividend: 1783's dividend payments have increased, but the company has only paid a dividend for 5 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (56.4%), 1783's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (30.8%), 1783's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure


CEO

Ching-Ting Chen

0.83yr

Tenure

Ms. Ching-Ting Chen serves as Head of Research & Design Center at TCI Co., Ltd. since February 5, 2020. She served as R&D chief, TCI Co., Ltd.She holds Master’s Degree in Chemistry, National Taiwan Univer...


Board Members

Experienced Board: 1783's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 1783?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Maxigen Biotech Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Maxigen Biotech Inc.
  • Ticker: 1783
  • Exchange: TWSE
  • Founded: 1998
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: NT$3.142b
  • Shares outstanding: 77.00m
  • Website: https://mbi-bio.com

Location

  • Maxigen Biotech Inc.
  • No. 88, Keji 1st Road
  • Guishan District
  • Taoyuan City
  • 333
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1783TWSE (Taiwan Stock Exchange)YesCommon StockTWTWDMay 2011

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.